🧠 Food for thought

Implications, context, and why it matters.

Nanyang Biologics pursues SPAC listing and investors should check trust and redemptions

• Nanyang Biologics plans to merge with RF Acquisition Corp II, a special-purpose acquisition company (SPAC), to list on Nasdaq. A May 17, 2024 prospectus is public, yet filings do not state the trust balance or likely redemptions, and many SPACs see high redemptions 1.
• Public notices list no private investment in public equity (PIPE) financing or a minimum cash requirement. Nanyang Biologics could list with limited cash. The deal pegs pre-transaction equity value near $1.5 billion, which is not cash raised 2.
• Investors should wait for the proxy or registration statement and U.S. Securities and Exchange Commission (SEC) filings that detail the trust balance, any backstops or PIPEs, and sponsor dilution terms before judging the funding on offer 3.

US pharma reshoring may lift CDMOs adding sterile and biologics capacity

• president Trump proposed a 100% tariff on branded drugs with a delay of up to 18 months. That could push manufacturing back to the US as the contract development and manufacturing organization (CDMO) market nears $230 billion by 2030 4.
• Equipment makers plus digital tool vendors can target CDMOs that add sterile fill-finish, antibody-drug conjugates, and cell or gene therapy lines 5.
• Buyers can watch US CDMOs expanding in oncology and gene therapies to secure licensing or manufacturing work from intellectual property owners such as Nanyang Biologics seeking US partners to limit tariff risk 5.